Provided is an anti-human CD40 antibody that is substantially antagonistic to a human CD40 antigen on the dendritic cell (DC) surface. And it is an agonistic anti-human CD40 antibody that is expected to have a therapeutic effect higher than those of conventional anti-human CD40 antibodies.